Moderna (MRNA) - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US60770K1079

Vaccines, Therapeutics, mRNA

Moderna, Inc. is a biotechnology company that pioneers the development of messenger RNA (mRNA) therapeutics and vaccines to tackle a wide range of diseases. With a focus on infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases, the company is dedicated to improving human health globally.

Moderna's vaccine portfolio is extensive, covering respiratory diseases such as COVID-19, influenza, and respiratory syncytial virus. They also have vaccines in development for latent diseases like cytomegalovirus, epstein-barr virus, and herpes simplex virus. Furthermore, they are working on vaccines for public health threats like Zika, Nipah, and Mpox, as well as infectious diseases like Lyme and norovirus.

Beyond vaccines, Moderna is also exploring innovative therapeutics, including systemic secreted and cell surface therapeutics, cancer vaccines, and intratumoral immuno-oncology products. They are also working on rare disease intracellular therapeutics and inhaled pulmonary therapeutics, showcasing their commitment to addressing unmet medical needs.

Moderna has established strategic alliances and collaborations with prominent organizations, including AstraZeneca, Merck & Co., Inc, Vertex Pharmaceuticals Incorporated, and the Bill & Melinda Gates Foundation, among others. These partnerships enable the company to accelerate its research and development efforts, leveraging the expertise of its partners to drive innovation.

Founded in 2010, Moderna, Inc. is headquartered in Cambridge, Massachusetts, and has undergone significant growth, including a name change from Moderna Therapeutics, Inc. in 2018. Today, the company continues to push the boundaries of mRNA technology, driving progress toward a healthier future for all.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Moderna (MRNA) - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Moderna (MRNA) - Stock Price & Dividends

MRNA Stock Overview

Market Cap in USD 57,873m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2018-12-07

MRNA Stock Ratings

Growth 5y 45.9
Fundamental -61.6
Dividend -
Rel. Performance vs Sector 0.58
Analysts 3.65/5
Fair Price Momentum 137.19 USD
Fair Price DCF -

MRNA Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

MRNA Growth Ratios

Growth 12m 11.00%
Growth Correlation 12m 9%
Growth Correlation 3m 66%
CAGR 5y 55.37%
CAGR/Mean DD 5y 1.27
Sharpe Ratio 12m 0.11
Alpha vs SP500 12m -15.59
Beta vs SP500 5y weekly 1.00
ValueRay RSI 40.04
Volatility GJR Garch 1y 50.11%
Price / SMA 50 7.42%
Price / SMA 200 33.87%
Current Volume 3366.6k
Average Volume 20d 4796.3k

External Links for MRNA Stock

Wall Street JournalBenzingaYahoo Finance
Fund Manager Positions
What is the price of MRNA stocks?
As of June 18, 2024, the stock is trading at USD 137.90 with a total of 3,366,555 shares traded.
Over the past week, the price has changed by -7.19%, over one month by +3.76%, over three months by +32.27% and over the past year by +7.12%.
What are the forecast for MRNA stock price target?
According to ValueRays Forecast Model, MRNA Moderna will be worth about 152.8 in June 2025. The stock is currently trading at 137.90. This means that the stock has a potential upside of +10.78%.
Issuer Forecast Upside
Wallstreet Target Price 142.2 3.12
Analysts Target Price 167.7 21.6
ValueRay Target Price 152.8 10.8